| Identification | Back Directory | [Name]
2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]- | [CAS]
932373-87-0 | [Synonyms]
GSK-1034702 HCl
2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-
4-fluoro-6-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one | [Molecular Formula]
C18H24FN3O2 | [MOL File]
932373-87-0.mol | [Molecular Weight]
333.4 |
| Hazard Information | Back Directory | [Uses]
GSK1034702 is a M1 mAChR allosteric agonist. GSK1034702 shows procognitive effects in rodents. GSK1034702 modulates hippocampal function to improve memory encoding in nicotine abstinence model of cognitive dysfunction[1]. | [References]
[1] Bradley SJ, et al. Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Mol Pharmacol. 2018 Jun;93(6):645-656. DOI:10.1124/mol.118.111872
[2] Nathan PJ, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. DOI:10.1017/S1461145712000752 |
|
|